Lloyd Emerson Johnson - 24 Jul 2026 Form 4 Insider Report for HAEMONETICS CORP (HAE)

Reporting relationship: Director
Issuer ticker: HAE
Reported as of: 24 Jul 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 28 Jul 2026, 16:56:30 UTC
Prior SEC filing: 01 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ Thomas V. Powers, attorney-in-fact for Mr. Johnson

Key filing fact

Lloyd Emerson Johnson filed Form 4 for HAEMONETICS CORP (HAE) on 28 Jul 2026.

Key facts

This page summarizes Lloyd Emerson Johnson's Form 4 filing for HAEMONETICS CORP (HAE).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 28 Jul 2026, 16:56.

Change

Previous filing in this sequence was filed on 01 Apr 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001708823 Primary reporting owner

Johnson Lloyd Emerson

Relationship: Director
Address: 125 SUMMER STREET, BOSTON
Signature: /s/ Thomas V. Powers, attorney-in-fact for Mr. Johnson
Signature date: 28 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

HAE transaction

Common Stock

Award

Transaction value
Shares: +2,538
Change %: +20%
Price
Shares after: 15,471
Date: 24 Jul 2026
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.

Footnote F2

Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.